Up next

Autoplay

How to treat AL amyloidosis in 2020?

3 Views • 11/23/23
Share
Embed
administrator
administrator
Subscribers
0

Suzanne Lentzsch, MD, PhD, Columbia University and New York Presbyterian Hospital, New York, NY, discusses treatment options for light chain (AL) amyloidosis, including how the results of the ANDROMEDA study (NCT03201965) evaluating daratumumab plus CyBorD may represent a new approach to patients with amyloidosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay